BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19717384)

  • 1. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
    Martin MG; Vij R
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):320-3. PubMed ID: 19717384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
    Galli M; Elice F; Crippa C; Comotti B; Rodeghiero F; Barbui T
    Haematologica; 2004 Sep; 89(9):1141-2. PubMed ID: 15377478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboembolism in patients on thalidomide for myeloma.
    Bowcock SJ; Rassam SM; Ward SM; Turner JT; Laffan M
    Hematology; 2002 Feb; 7(1):51-3. PubMed ID: 12171777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arterial and venous thrombotic complications with thalidomide in multiple myeloma.
    Alkindi S; Dennison D; Pathare A
    Arch Med Res; 2008 Feb; 39(2):257-8. PubMed ID: 18164975
    [No Abstract]   [Full Text] [Related]  

  • 5. [Thalidomide and thrombosis].
    Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L
    Ann Dermatol Venereol; 2000 Feb; 127(2):171-4. PubMed ID: 10739975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Left atrial thrombus in multiple myeloma treated with thalidomide].
    Jégo C; Barbou F; Laurent P; Gisserot O; Cellarier G; Bonal J; Bouchiat C; Landais C; de Jaureguiberry JP; Dussarat GV
    Arch Mal Coeur Vaiss; 2003 Oct; 96(10):1006-10. PubMed ID: 14653064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma and treatment-related thromboembolism: oncology nurses' role in prevention, assessment, and diagnosis.
    Wiley KE
    Clin J Oncol Nurs; 2007 Dec; 11(6):847-51. PubMed ID: 18063543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should we screen patients for inherited thrombophilia before starting thalidomide?
    Otrock ZK; Mahfouz RA; El-Hajj II; Harb MI; Sawaya RA
    Am J Clin Oncol; 2006 Feb; 29(1):100-1. PubMed ID: 16462512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.
    Gieseler F
    Thromb Haemost; 2008 Jun; 99(6):1001-7. PubMed ID: 18521500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
    Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
    Radocha J; Maisnar V
    Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
    Katodritou E; Gastari V; Verrou E; Hadjiaggelidou C; Varthaliti M; Georgiadou S; Laschos K; Xirou P; Yiannaki E; Constantinou N; Markala D; Zervas K
    Leuk Res; 2009 Aug; 33(8):1137-40. PubMed ID: 19250676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
    Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
    Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapies in myeloma.
    Hayden PJ; Mitsiades CS; Anderson KC; Richardson PG
    Curr Opin Hematol; 2007 Nov; 14(6):609-15. PubMed ID: 17898564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
    Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide and thrombosis in patients with multiple myeloma.
    Camba L; Peccatori J; Pescarollo A; Tresoldi M; Corradini P; Bregni M
    Haematologica; 2001 Oct; 86(10):1108-9. PubMed ID: 11602422
    [No Abstract]   [Full Text] [Related]  

  • 18. Deep vein thrombosis occurring on treatment of patients receiving thalidomide with erythropoietin.
    Chennuru S; Baumann MA
    Intern Med J; 2007 Jul; 37(7):506-7. PubMed ID: 17547733
    [No Abstract]   [Full Text] [Related]  

  • 19. Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature.
    Alexandrescu DT; Koulova L; Wiernik PH
    Clin Exp Dermatol; 2005 Jul; 30(4):391-4. PubMed ID: 15953079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.